Search - tctmd.com

Displaying 1 - 20 of 64

Sort: Relevancy | Date

Presentation TCTAP 2018

To Treat or Not To Treat For Gray Zone FFR (0.76~0.80)

Presenter: Seung-Jung Park

April 28, 2018

Presentation TCTAP 2018

OPTIMA Trial: P2Y12 Dose Adjustment for East-Asian ACS Patients

Presenter: Duk-Woo Park

April 28, 2018

Presentation TCTAP 2018

Distal Left Main Bifurcation PCI: Concept is More Important

Presenter: Jung-Min Ahn

April 28, 2018

Presentation TCTAP 2018

DECISION-CTO: Updated QOL and Long-Term Outcomes

Presenter: Seung-Whan Lee

April 28, 2018

Presentation TCTAP 2018

All Data from Real World FFR Registry

Presenter: Seung-Jung Park

April 28, 2018

Presentation TCTAP 2013

Update of New TAVI Indications

Presenter: Thierry Lef?vre

April 25, 2013

Presentation TCTAP 2013

Trends in the Outcomes of PCI with the Routine Incorporation of Fractional Flow Reserve in Real Practice

Presenter: Seung-Jung Park

April 25, 2013

Presentation TCTAP 2013

Transcatheter Aortic Valve Implantation in Patients with an Annulus Dimension Suitable for either the Edwards Valve or the CoreValve

Presenter: Yusuke Watanabe

April 25, 2013

Presentation TCTAP 2013

TAVI Technology and Procedural Changes

Presenter: Eberhard Grube

April 25, 2013

Presentation TCTAP 2013

Paravalvular AI: Incidence, Cause and Treatment

Presenter: Raj R. Makkar

April 25, 2013

Presentation TCTAP 2013

Lessons from European Registries

Presenter: Alain Cribier

April 25, 2013

Presentation TCTAP 2013

In-hospital outcome of interventional treatment in elderly patients with acute coronary syndromes

Presenter: W. Wojakowski

April 25, 2013

Presentation TCTAP 2013

How to Choose TAVI or SAVR

Presenter: I. Sheiban

April 25, 2013

Presentation TCTAP 2013

ESSENCE-DIABETES II Trial

Presenter: Gyung-Min Park

April 25, 2013

Presentation TCTAP 2013

Comparison of Platinum Chromium Versus Cobalt Chromium Everolimus-Eluting Stent in Real World Practice: Outcomes from the Multicenter Prospective IRIS-DES Registry

Presenter: Jung-Min Ahn

April 25, 2013

Presentation TCTAP 2013

Clinical Outcomes after Transcatheter Aortic Valve Replacement (TAVR) Using Valve Academic Research Consortium (VARC) Definitions: A Weighted Meta-Analysis of 3,519 Patients from 16 Studies

Presenter: Philippe Généreux

April 25, 2013

Presentation TCTAP 2013

Can We Prevent Conduction Disturbances?

Presenter: Corrado Tamburino

April 25, 2013

Presentation TCTAP 2013

Can We Afford TAVR? Economic Insights from the PARTNER Trial

Presenter: David J. Cohen

April 25, 2013

Presentation TCTAP 2013

The Gold Standard for PCI Will Be Bioabsorbable DES

Presenter: Ron Waksman

April 24, 2013

Presentation TCTAP 2013

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Presenter: Matthew J. Price

April 24, 2013

Advertisement

To Treat or Not To Treat For Gray Zone FFR (0.76~0.80)

OPTIMA Trial: P2Y12 Dose Adjustment for East-Asian ACS Patients

Distal Left Main Bifurcation PCI: Concept is More Important

DECISION-CTO: Updated QOL and Long-Term Outcomes

All Data from Real World FFR Registry

Update of New TAVI Indications

Trends in the Outcomes of PCI with the Routine Incorporation of Fractional Flow Reserve in Real Practice

Transcatheter Aortic Valve Implantation in Patients with an Annulus Dimension Suitable for either the Edwards Valve or the CoreValve

TAVI Technology and Procedural Changes

Paravalvular AI: Incidence, Cause and Treatment

Lessons from European Registries

In-hospital outcome of interventional treatment in elderly patients with acute coronary syndromes

How to Choose TAVI or SAVR

ESSENCE-DIABETES II Trial

Comparison of Platinum Chromium Versus Cobalt Chromium Everolimus-Eluting Stent in Real World Practice: Outcomes from the Multicenter Prospective IRIS-DES Registry

Clinical Outcomes after Transcatheter Aortic Valve Replacement (TAVR) Using Valve Academic Research Consortium (VARC) Definitions: A Weighted Meta-Analysis of 3,519 Patients from 16 Studies

Can We Prevent Conduction Disturbances?

Can We Afford TAVR? Economic Insights from the PARTNER Trial

The Gold Standard for PCI Will Be Bioabsorbable DES

The Future Is: New Antiplatelet Agents, Selective Platelet Function Testing, and Patient-Specific DAPT Duration

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content